EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.80
−3.13%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.03
From 52W high−51.08%
Volume1.84M
Market cap$348.66M
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataSep 18, 2026
Open
$7.03
From 52W high
−51.08%
Volume
1.84M
Market cap
$348.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−33.4x
P/E (TTM)
—
RSI (14)
63.3
MomentumView details →
1D Return
−3.13%
YTD Return
−44.01%
SummaryUpdated Jun 1, 2026
Emergent BioSolutions Inc. (NYSE:EBS) is a specialized life sciences company founded in 1998 and headquartered in Gaithersburg, Maryland. The company went public in 2006 and has evolved into a leading provider of medical countermeasures and emergency response solutions for public health threats. Emergent focuses on addressing chemical, biological, radiological, nuclear, and explosive threats, as well as emerging infectious diseases and opioid overdose emergencies. The company has undergone significant strategic transformation in recent years, streamlining operations and focusing on its core competencies in biodefense and overdose prevention.
Similar companies
Latest newsMore news →
Emergent BioSolutions will host a ribbon cutting ceremony on September 16, 2026 to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility.5d agoEmergent BioSolutions Inc. completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, spending about $68 million in cash at an average price of 90.6% of face value, reducing the outstanding balance to approximately $364.7 million.17d ago